Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. (2r)-2-amino-3-phenylpropyl Carbamate
2. (r)-2-amino-3-phenylpropylcarbamate Hydrochloride
3. Adx-n05
4. Benzenepropanol, Beta-amino-, Carbamate (ester), (betar)-
5. Jzp-110
6. Solriamfetol
7. Sunosi
1. Jzp-110 Hydrochloride
2. 178429-65-7
3. Solriamfetol (hydrochloride)
4. K7ro88sp7a
5. Solriamfetol Hydrochloride [usan]
6. Solriamfetol Hydrochloride (usan)
7. R-228060
8. Sunosi (tn)
9. Unii-k7ro88sp7a
10. Adx-n05 Hydrochloride
11. Ykp-10a Hydrochloride
12. Schembl8430382
13. Adx-n-05 Hydrochloride
14. Skl-n-05 Hydrochloride
15. Chembl4297212
16. Dtxsid101027927
17. R-228060 Hydrochloride
18. Hy-109043a
19. Solriamfetol Hydrochloride [mi]
20. Solriamfetol Hydrochloride [who-dd]
21. Cs-0112102
22. O-carbamoyl-(d)-phenylalaninol Hydrochloride
23. D11328
24. Solriamfetol Hydrochloride [orange Book]
25. (d)-o-carbamoylphenylalaninol Hydrochloride Salt
26. R228060;jzp-110;adx-n05;skl-n05;ykp-10
27. (2r)-2-amino-3-phenylpropyl Carbamate, Monohydrochloride
28. (betar)-beta-amino-benzenepropanol 1-carbamate Hydrochloride (1:1)
29. (r)-(+)-2-amino-1-carbamoyloxy-3-phenylpropane Hydrochloride
30. Benzenepropanol, .beta.-amino-, 1-carbamate, Hydrochloride (1:1), (.beta.r)-
31. 561069-23-6
Molecular Weight | 230.69 g/mol |
---|---|
Molecular Formula | C10H15ClN2O2 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 5 |
Exact Mass | 230.0822054 g/mol |
Monoisotopic Mass | 230.0822054 g/mol |
Topological Polar Surface Area | 78.3 Ų |
Heavy Atom Count | 15 |
Formal Charge | 0 |
Complexity | 179 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Sunosi is indicated to improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy (with or without cataplexy).
Sunosi is indicated to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by primary OSA therapy, such as continuous positive airway pressure (CPAP).
N06BA14
Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-03-16
Pay. Date : 2023-01-25
DMF Number : 36949
Submission : 2022-03-30
Status : Active
Type : II
NDC Package Code : 53747-100
Start Marketing Date : 2022-03-30
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-04-28
Pay. Date : 2023-01-09
DMF Number : 37929
Submission : 2023-01-10
Status : Active
Type : II
NDC Package Code : 59651-756
Start Marketing Date : 2023-11-07
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (50kg/50kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2022-12-16
Pay. Date : 2022-11-14
DMF Number : 34741
Submission : 2020-03-31
Status : Active
Type : II
Date of Issue : 2023-11-28
Valid Till : 2026-11-28
Written Confirmation Number : WC-0310
Address of the Firm :
NDC Package Code : 66039-953
Start Marketing Date : 2020-09-08
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-04-04
Pay. Date : 2022-12-19
DMF Number : 37548
Submission : 2022-12-28
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-05-16
Pay. Date : 2023-04-12
DMF Number : 38280
Submission : 2023-04-18
Status : Active
Type : II
NDC Package Code : 65977-0140
Start Marketing Date : 2019-12-17
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-02-15
Pay. Date : 2023-02-03
DMF Number : 36951
Submission : 2022-03-28
Status : Active
Type : II
Date of Issue : 2022-07-23
Valid Till : 2025-05-09
Written Confirmation Number : WC-0385
Address of the Firm :
Date of Issue : 2023-11-28
Valid Till : 2026-11-28
Written Confirmation Number : WC-0310
Address of the Firm : Plot No. Z-103/l, Dahej SEZ, Phase II, Dahej, Dist-Bharuch, Gujarat, India
Date of Issue : 2022-07-23
Valid Till : 2025-05-09
Written Confirmation Number : WC-0385
Address of the Firm : Survey No.- 85 to 88, N.H. No.-8, Naugama, At & Post-Mandva, Tal. - Ankleshwar, ...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
37
PharmaCompass offers a list of Solriamfetol Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Solriamfetol Hydrochloride manufacturer or Solriamfetol Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Solriamfetol Hydrochloride manufacturer or Solriamfetol Hydrochloride supplier.
PharmaCompass also assists you with knowing the Solriamfetol Hydrochloride API Price utilized in the formulation of products. Solriamfetol Hydrochloride API Price is not always fixed or binding as the Solriamfetol Hydrochloride Price is obtained through a variety of data sources. The Solriamfetol Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A JZP-110 hydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of JZP-110 hydrochloride, including repackagers and relabelers. The FDA regulates JZP-110 hydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. JZP-110 hydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of JZP-110 hydrochloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A JZP-110 hydrochloride supplier is an individual or a company that provides JZP-110 hydrochloride active pharmaceutical ingredient (API) or JZP-110 hydrochloride finished formulations upon request. The JZP-110 hydrochloride suppliers may include JZP-110 hydrochloride API manufacturers, exporters, distributors and traders.
click here to find a list of JZP-110 hydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A JZP-110 hydrochloride DMF (Drug Master File) is a document detailing the whole manufacturing process of JZP-110 hydrochloride active pharmaceutical ingredient (API) in detail. Different forms of JZP-110 hydrochloride DMFs exist exist since differing nations have different regulations, such as JZP-110 hydrochloride USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A JZP-110 hydrochloride DMF submitted to regulatory agencies in the US is known as a USDMF. JZP-110 hydrochloride USDMF includes data on JZP-110 hydrochloride's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The JZP-110 hydrochloride USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of JZP-110 hydrochloride suppliers with USDMF on PharmaCompass.
A JZP-110 hydrochloride written confirmation (JZP-110 hydrochloride WC) is an official document issued by a regulatory agency to a JZP-110 hydrochloride manufacturer, verifying that the manufacturing facility of a JZP-110 hydrochloride active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting JZP-110 hydrochloride APIs or JZP-110 hydrochloride finished pharmaceutical products to another nation, regulatory agencies frequently require a JZP-110 hydrochloride WC (written confirmation) as part of the regulatory process.
click here to find a list of JZP-110 hydrochloride suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing JZP-110 hydrochloride as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for JZP-110 hydrochloride API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture JZP-110 hydrochloride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain JZP-110 hydrochloride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a JZP-110 hydrochloride NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of JZP-110 hydrochloride suppliers with NDC on PharmaCompass.
JZP-110 hydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of JZP-110 hydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right JZP-110 hydrochloride GMP manufacturer or JZP-110 hydrochloride GMP API supplier for your needs.
A JZP-110 hydrochloride CoA (Certificate of Analysis) is a formal document that attests to JZP-110 hydrochloride's compliance with JZP-110 hydrochloride specifications and serves as a tool for batch-level quality control.
JZP-110 hydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each JZP-110 hydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
JZP-110 hydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (JZP-110 hydrochloride EP), JZP-110 hydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (JZP-110 hydrochloride USP).